Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,687,572 | -241,361 | -145,226 | -81,768 | -76,124 |
| Depreciation Amortization | 2,285 | 6,090 | 4,673 | 2,429 | 11,208 |
| Accounts receivable | 381 | -535 | 130 | -167 | 117 |
| Accounts payable and accrued liabilities | 17,903 | 2,109 | -705 | -4,642 | 10,426 |
| Other Working Capital | 52,051 | 15,348 | 3,162 | -17,516 | 12,691 |
| Other Operating Activity | -1,954,601 | 25,040 | 22,665 | 21,341 | -6,286 |
| Operating Cash Flow | $-194,409 | $-193,309 | $-115,301 | $-80,323 | $-47,968 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,597 | -4,593 | -686 | -809 | -1,364 |
| Investing Cash Flow | $-2,597 | $-4,593 | $-686 | $-809 | $-1,364 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 0 | 128,863 | 39,992 | 46,813 |
| Debt Repayment | N/A | N/A | N/A | N/A | -5,458 |
| Common Stock Issued | 71,678 | 202,316 | 2,757 | 3,956 | 136,877 |
| Other Financing Activity | 0 | -355 | 126,931 | 39,821 | -11,776 |
| Financing Cash Flow | $71,678 | $201,961 | $258,551 | $83,769 | $166,456 |
| Beginning Cash Position | 277,924 | 273,865 | 131,301 | 128,664 | 11,540 |
| End Cash Position | 152,596 | 277,924 | 273,865 | 131,301 | 128,664 |
| Net Cash Flow | $-125,328 | $4,059 | $142,564 | $2,637 | $117,124 |
| Free Cash Flow | |||||
| Operating Cash Flow | -194,409 | -193,309 | -115,301 | -80,323 | -47,968 |
| Capital Expenditure | -2,597 | -4,593 | -686 | -864 | -1,364 |
| Free Cash Flow | -197,006 | -197,902 | -115,987 | -81,187 | -49,332 |